+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Infertility Drugs Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5805789
The global infertility drugs market value was USD 3.7 billion in 2022, driven by the increasing prevalence of infertility due to factors such as age, lifestyle changes, and medical conditions across the globe. The market size is anticipated to grow at a CAGR of 5.5% during the forecast period of 2023-2031 to achieve a value of USD 6 billion by 2031.


Infertility drugs play a crucial role in the treatment of infertility, a condition affecting millions of couples worldwide. These drugs are designed to help regulate or stimulate ovulation, enhance reproductive hormone production, and improve fertility outcomes. They are often prescribed as a first-line treatment for various causes of infertility, such as hormonal imbalances, polycystic ovary syndrome (PCOS), and unexplained infertility.

Key Trends in the Infertility Drugs Market

Some key trends involved in the infertility drugs market are as follows:
  • Advancements in Assisted Reproductive Technologies (ART): The field of infertility treatment has witnessed significant advancements in assisted reproductive technologies, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT). These technologies, combined with the use of infertility drugs, have led to improved success rates and better outcomes for couples seeking fertility treatment
  • Growing Demand for Personalized and Tailored Treatments: With increasing awareness and understanding of individual patient characteristics, there is a growing demand for personalized and tailored infertility treatments. Healthcare providers are using advanced diagnostic techniques, such as genetic testing and hormone profiling, to identify specific causes of infertility and prescribe targeted drug therapies. This trend aims to optimize treatment efficacy and minimize potential side effects
  • Development of New Drug Formulations: Pharmaceutical companies are continuously investing in research and development to develop new and improved infertility drug formulations. This includes the development of more potent and selective drugs, extended-release formulations for convenience, and combination therapies to address multiple underlying causes of infertility. These advancements offer new treatment options and greater flexibility for healthcare providers and patients
  • Increasing Focus on Male Infertility: Traditionally, infertility treatment has predominantly focused on female infertility. However, there is a growing recognition of male factor infertility and the importance of addressing male reproductive health. As a result, there is an increasing emphasis on developing drugs and treatment strategies specifically targeting male infertility, including medications that improve sperm quality and quantity

Infertility Drugs Market Segmentations

Market Breakup by Drug Class

  • Clomiphene Citrate
  • Gonadotropins
  • Aromatase Inhibitors
  • Selective Estrogen Receptor Modulators (SERMs)
  • Dopamine Agonists
  • Others

Market Breakup by Gender

  • Male
  • Female
  • Others

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Infertility Drugs Market Scenario

The market for infertility drugs is a significant and growing segment within the broader field of reproductive medicine. Infertility affects a substantial number of couples worldwide, leading to an increasing demand for effective treatment options. Infertility drugs play a crucial role in addressing hormonal imbalances, regulating ovulation, and improving fertility outcomes.

The market is driven by several factors, including the rising prevalence of infertility due to factors such as age, lifestyle changes, and medical conditions. Additionally, the increasing awareness and acceptance of infertility as a medical condition have reduced the stigma associated with seeking treatment, leading more couples to explore infertility drugs as a viable solution.

Geographically, the market for infertility drugs is witnessing growth across various regions, including North America, Europe, Asia Pacific, and the rest of the world. Factors such as the availability of advanced healthcare infrastructure, favourable reimbursement policies, and the presence of key pharmaceutical companies are contributing to market expansion.

Infertility Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Merck KGaA
  • Abbott Laboratories
  • Mankind Pharma
  • Pfizer Inc
  • Ferring Pharmaceuticals Inc
  • Thermo Fisher Scientific, Inc
  • Genea Biomedx
  • IVFtech ApS

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Infertility Drugs Market Overview
3.1 Global Infertility Drugs Market Historical Value (2016-2022)
3.2 Global Infertility Drugs Market Forecast Value (2023-2031)
4 Global Infertility Drugs Market Landscape
4.1 Global Infertility Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Infertility Drugs Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Gender
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by Distribution Channel
5 Global Infertility Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Infertility Drugs Market Segmentation
6.1 Global Infertility Drugs Market by Drug Class
6.1.1 Market Overview
6.1.2 Clomiphene Citrate
6.1.3 Gonadotropins
6.1.4 Aromatase Inhibitors
6.1.5 Selective Estrogen Receptor Modulators (SERMs)
6.1.6 Dopamine Agonists
6.1.7 Others
6.2 Global Infertility Drugs Market by Gender
6.2.1 Market Overview
6.2.2 Male
6.2.3 Female
6.2.4 Others
6.3 Global Infertility Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Others
6.4 Global Infertility Drugs Market by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacy
6.4.3 Retail Pharmacy
6.4.4 Online Pharmacy
6.4.5 Others
6.5 Global Infertility Drugs Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Infertility Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Infertility Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Infertility Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Infertility Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Infertility Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Supplier Landscape
18.1 Merck KGaA
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Abbott Laboratories
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Mankind Pharma
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Pfizer Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Ferring Pharmaceuticals Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Thermo Fisher Scientific, Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Genea Biomedx
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 IVFtech ApS
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
19 Global Infertility Drugs Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket

Companies Mentioned

  • Merck KGaA
  • Abbott Laboratories
  • Mankind Pharma
  • Pfizer Inc.
  • Ferring Pharmaceuticals Inc.
  • Thermo Fisher Scientific Inc.
  • Genea Biomedx
  • IVFtech ApS



Table Information